COMPASS Pathways (CMPS) Earnings Date & Reports

Key Takeaways

• COMPASS Pathways reported a third-quarter 2026 net loss of $9.83 million, sharply narrower than the $137.72 million loss in the same period a year earlier.
• Diluted loss per share was $0.31, versus $1.44 a year ago; the GAAP loss of $0.31 per share beat analyst consensus by $0.10.
• The company remained pre-revenue, posting $0.0 million in sales as expected, while operating loss widened as launch preparation costs climbed.
• Cash and cash equivalents reached $443.98 million at September 30, 2026, up from $149.6 million at the end of 2025, funding operations into 2028.
• Management said the rolling New Drug Application (NDA) for COMP360 in treatment-resistant depression will be completed within two weeks, with a targeted commercial launch in the first half of 2027.
• For more on CMPS, you can review its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• To discover new trade ideas powered by artificial intelligence, explore the Trending AI Robots.

Earnings Context and Why It Matters

COMPASS Pathways is a clinical-stage biotechnology company developing COMP360, an investigational synthetic psilocybin therapy for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Because the company has not yet launched a commercial product, its quarterly results carry no revenue and are measured instead by cash burn, clinical progress, and regulatory milestones. The third quarter of 2026 matters most because COMP360's rolling New Drug Application is nearing completion, positioning COMPASS as a potential first mover in a new category of mental health treatments. With a National Priority Voucher potentially enabling an accelerated review, investors are watching this report less for the loss figure itself and more for signals on approval timing, launch readiness, and the strength of the balance sheet.

Reported Results

For the three months ended September 30, 2026, COMPASS Pathways reported a net loss of $9.83 million, compared with $137.72 million in the prior-year quarter. The narrower loss was driven largely by a $40.78 million non-cash fair-value gain on warrant liabilities, versus a $101.32 million loss in the same period a year ago. On a diluted basis, the company posted a loss of $0.31 per share, improved from $1.44 per share a year earlier and ahead of consensus expectations.

Revenue remained at zero, consistent with a pre-commercial company. Operating loss widened to $56.44 million from $40.54 million, as selling, general and administrative (SG&A) expenses climbed to $32.98 million from $13.21 million a year ago, reflecting investment in commercial infrastructure ahead of a potential 2027 launch. Research and development (R&D) spending declined to $23.46 million from $27.33 million as Phase 3 TRD trial costs rolled off.

For the nine months ended September 30, 2026, net loss was $172.42 million, compared with $193.98 million a year earlier, and diluted loss per share was $1.35 versus $2.09.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring clinical-stage names like COMPASS Pathways, it offers a structured way to surface opportunities across the broader biotech and healthcare landscape.

Market Reaction and Investor Sentiment

Shares of COMPASS Pathways moved higher following the November 3, 2026 report, reflecting relief that the bottom-line beat coincided with a clearer timeline for the COMP360 filing. Because the company is pre-revenue, the market's response was driven less by the loss-per-share figure than by the regulatory narrative. Management confirmed that the rolling NDA would be completed within two weeks and reiterated confidence that the National Priority Voucher could support a one-to-two-month review target at the U.S. Food and Drug Administration (FDA).

Sentiment remains shaped by both opportunity and risk. On the positive side, the company highlighted a stronger cash position and commercial preparation. On the cautionary side, investors continue to weigh uncertainty around Drug Enforcement Administration (DEA) rescheduling, state-level rescheduling timelines, reimbursement code transitions, and speculation about potential competing psilocybin programs.

Forward Outlook and Key Factors to Monitor

The next several quarters will be defined by execution rather than financial results. The immediate milestone is completion of the NDA submission, expected within two weeks of the report. From there, attention turns to the FDA's acceptance and review timeline, with the National Priority Voucher potentially compressing the process to a one-to-two-month review window.

Investors should monitor the rescheduling pathway closely. Federal DEA rescheduling must be followed by state-level actions, and management has indicated that states representing more than 93% of the U.S. population have signaled intent to reschedule within 30 days of federal action. Reimbursement is another key factor, as the company expects a transition from Category III to Category I billing codes over roughly 12 to 18 months, with patient support programs bridging the early launch period.

Commercial readiness will also be a focus. COMPASS has filled its planned non-field commercial roles and is now building a field force, while the network of interventional psychiatry treatment centers has grown beyond 8,500 sites. Management plans to report launch metrics such as Risk Evaluation and Mitigation Strategy (REMS) certifications, prescriptions, prescribers, and payer access through 2027. With roughly $444 million in cash, the company has stated its balance sheet is sufficient to carry it through launch and into 2028, though rising commercial spending is expected to persist as the organization scales toward a targeted first-half 2027 launch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations